Desperate Housewives' Delany to flack Pfizer's Caltrate

Share this article:
Desperate Housewives' Delany to flack Pfizer's Caltrate
Desperate Housewives' Delany to flack Pfizer's Caltrate
Desperate Housewives star Dana Delany will serve as the face of Pfizer's “Women Move the World” campaign for OTC calcium and vitamin D supplement Caltrate.

The 55-year-old actress, currently featured in TV's Body of Proof, will issue a “national call-to-action inviting women everywhere to share their individual stories and everyday accomplishments” through the brand's Facebook page and at Susan G. Komen Race for the Cure events, for which the brand will be a national sponsor. Some women sharing girl power-themed tales of their accomplishments on Facebook will be tapped to appear in ads for the product, the company said.

“I want to thank the women in my life who have inspired me to join Caltrate in this celebration,” said Delany in a statement. “Together, we encourage all women to keep their bodies strong, so they can keep moving themselves and the world forward.”

Marina Maher Communications is handling the PR campaign.

Susan G. Komen for the Cure supports breast cancer research. Pfizer will donate $100,000 to the charity through March 2012 in Caltrate's name. The company will post Caltrate booths at Komen races, where attendees can get samples or submit their stories to the campaign.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...